Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Remdesivir Data Looks Encouraging, But Many Unknowns Remain - RBC Capital

April 17, 2020 7:48 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) but remains ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments